Search

Displaying results 671 - 680 of 10000 in total
  1. Drug

    Fluconazole

    go.drugbank.com/drugs/DB00196
    ApprovedInvestigational

    It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. … It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.[A174325]

    Products: FLUCONAZOLO EG, Fluconazole in Dextrose
  2. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    It was first approved by the FDA in 2017. … It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.

    Products: Dupixent 300 mg Solution for Injection in Pre-filled Syringe, Dupixent 200mg Solution for Injection in Pre-Filled Syringe
  3. Drug

    Lidocaine

    go.drugbank.com/drugs/DB00281
    ApprovedInvestigationalVet approved

    Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication [T583]. … Regardless, lidocaine is currently available as a relatively non-expensive generic medication that is written for in millions of prescriptions internationally on a yearly basis.

    Synonyms: 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamideMixtures: EZ-Relief, Lidothol ES
  4. Drug

    Nicorandil

    go.drugbank.com/drugs/DB09220
    ApprovedInvestigationalWithdrawn

    Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. … It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels.

    Synonyms: N-(2-Hydroxyethyl)nicotinamide nitrate, N-(2-Hydroxyethyl)nicotinamide nitrate (ester)Categories: Vasodilators Used in Cardiac Diseases
  5. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    in Pompe disease. … ,[L45275] and the EMA fully approved the drug on March 27, 2023.

  6. Drug

    Agalsidase alfa

    go.drugbank.com/drugs/DB15874
    ApprovedInvestigational

    [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413]

  7. Drug

    Secukinumab

    go.drugbank.com/drugs/DB09029
    ApprovedInvestigational

    [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque

    Products: Fraizeron 150mg/ml solution for injection in pre-filled pen, Fraizeron 300mg/2ml solution for injection in pre-filled pen
  8. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).

    Mixtures: Suliqua Pen, Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled penCategories: Drugs Used in Diabetes
  9. Drug

    Zonisamide

    go.drugbank.com/drugs/DB00909
    ApprovedInvestigational

    The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383] … Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III.

    Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate